^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MAP3K1 mutation

i
Other names: MAP3K1, Mitogen-Activated Protein Kinase Kinase Kinase 1, MAPKKK1, MEKK1, MEKK, MAPK/ERK Kinase Kinase 1, MEK Kinase 1, MEKK 1, Mitogen-Activated Protein Kinase Kinase Kinase 1, E3 Ubiquitin Protein Ligase, MAP/ERK Kinase Kinase 1, SRXY6
Entrez ID:
Related biomarkers:
1m
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing. (PubMed, ESMO Open)
Cancer panel testing for cfDNA identified prognostic and predictive biomarkers for palbociclib add-on therapy after acquiring fulvestrant resistance in patients with HR+/HER2- ABC/MBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RUNX1 (RUNX Family Transcription Factor 1) • FOXA1 (Forkhead Box A1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
|
TP53 mutation • HR positive • HER-2 negative • PIK3CA mutation • ER mutation • AR mutation • ESR1 mutation • MAP3K1 mutation • FOXA1 mutation
|
Ibrance (palbociclib) • fulvestrant
4ms
Genomic Characteristics and Its Therapeutic Implications in Breast Cancer Patients with Detectable Molecular Residual Disease. (PubMed, Cancer Res Treat)
The Cell cycle pathway, defective DNA mismatch repair, and AID-mediated SHM were found to be the possible causes of detectable MRD. We also found the vast majority of patients with detectable MRD have the opportunity to access targeted therapy.
Journal
|
FLT1 (Fms-related tyrosine kinase 1) • POLD1 (DNA Polymerase Delta 1) • GNAS (GNAS Complex Locus) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • WWP2 (WW Domain Containing E3 Ubiquitin Protein Ligase 2)
|
ATM mutation • POLD1 mutation • MAP3K1 mutation
5ms
Collagen deposition in the breast cancer microenvironment correlates with ER-positive, Histological Grade I and low proliferation tumors. (SABCS 2023)
In addition, analyses of collagen-high patients from the METABRIC study indicated that most cases presented with PIK3CA, CBFB and MAP3K1 mutations, while through the g.Profiler software we identified collagen-high relevant gene signatures that encompassed gene ontology terms related to tissue development, extracellular matrix organization and cell migration. Collectively, our preliminary results indicate that ECM collagen deposition in breast cancer is characteristic of low-grade tumors with a better differentiation and possibly with a favorable prognosis.
Tumor mutational burden
|
ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
|
ER positive • PIK3CA mutation • MAP3K1 mutation
6ms
Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers. (PubMed, Genes (Basel))
We found similar mutational profiles between primary and paired recurrent tumors, suggesting that genomic features may be retained during local recurrence.
Journal • Tumor mutational burden • Discordant
|
TMB (Tumor Mutational Burden) • MUC16 (Mucin 16, Cell Surface Associated) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
|
MUC16 mutation • MAP3K1 mutation
10ms
Intramedullary tumor in adult with 1p/19q codeletion, FGFR1 mutation and DNA methylation profile of diffuse leptomeningeal glioneuronal tumor (AANP 2023)
DNA MP yielded a match with DLGNT though somewhat incongruent radiographic findings were present. These observations suggest that DLGNT may in fact originate from an intramedullary lesion with a propensity for leptomeningeal dissemination.
Clinical • Epigenetic controller
|
BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR1 (Fibroblast growth factor receptor 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • SYP (Synaptophysin) • OLIG2 (Oligodendrocyte Transcription Factor 2)
|
BRAF V600E • FGFR1 mutation • MAP3K1 mutation • SETD2 mutation
11ms
Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)-like change: clinicopathological and molecular characteristics. (PubMed, Histopathology)
Gene mutations along more advanced phases of the proposed FEL pathogenetic pathway in GJFA are unusual, and suggest a mechanism for more aggressive growth in these tumours.
Journal • Stroma
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • KMT2D (Lysine Methyltransferase 2D) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • BCOR (BCL6 Corepressor) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • CD34 (CD34 molecule) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
|
TP53 mutation • RB1 mutation • TERT mutation • TERT promoter mutation • MAP3K1 mutation • PGR expression • SETD2 mutation • CTNNB1 expression • TERT 124C>T
11ms
A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study. (ASCO 2023)
For breast cancer patients eligible for inclusion, patients were allocated to 2 cycles of chemotherapy using nab-paclitaxel with carboplatin...Group C were received dalpiciclib, letrozole and adebrelimab plus goserrelin if patient was premenopausal... From Nov 16, 2020 to Jun 10, 2022, 121 patients were enrolled... Neoadjuvant chemotherapy and neoadjuvant endocrine therapy are not mutually exclusive. The overall treatment strategy did not improve the efficacy, but there is still a possibility that some people can get an improvement from the strategy adjustment. Precision analysis may yield the characteristics of patients who would benefit from this shift in treatment strategy.
Clinical • P2 data
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ASXL1 (ASXL Transcriptional Regulator 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • IR (Insulin receptor) • GATA3 (GATA binding protein 3)
|
HER-2 positive • TP53 mutation • HR positive • HER-2 negative • PIK3CA mutation • ASXL1 mutation • RET mutation • HR positive + HER-2 negative • MAP3K1 mutation
|
carboplatin • albumin-bound paclitaxel • letrozole • AiRuiKang (dalpiciclib) • adebrelimab (SHR-1316)
2years
Spectrum of MAP3K1 mutations in breast cancer is luminal subtype-predominant and related to prognosis. (PubMed, Oncol Lett)
Moreover, the MAP3K1 methylation levels were reduced in primary breast cancer tissue, compared with normal tissue. Thus, the present findings identified MAP3K1 mutations in Chinese patients with breast cancer, and compared MAP3K1 mutations between the cohorts from Western and Eastern countries.
Journal
|
MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
|
MAP3K1 mutation
over2years
Targeted DNA and RNA Sequencing of Soft Tissue Spindle Cell Tumors Reveals a Rare MET-TFG and a Novel PWWP2A-RET Gene Fusions as well as Additional Recurrent PIK3CA Point Mutations (USCAP 2022)
Besides identifying several rare or novel kinase fusions genes, our analysis also revealed various additional mutations including recurrent PIK3CA point mutations. Although their significance is unknown, they might be responsible for progression of tumors with LG morphology (LNT, FTPH) into tumors with HG morphology and/or acquisition of a more aggressive biological potential. Targeted therapy is effective and significantly aids in successful treatment.
BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RET (Ret Proto-Oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ETV6 (ETS Variant Transcription Factor 6) • CD34 (CD34 molecule) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • NTRK (Neurotrophic receptor tyrosine kinase) • WWP2 (WW Domain Containing E3 Ubiquitin Protein Ligase 2)
|
PIK3CA mutation • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • RET fusion • ETV6-NTRK3 fusion • EML4-NTRK3 fusion • MAP3K1 mutation • KIT fusion
|
TruSight Oncology 500 Assay
over2years
Overlapping molecular features (proliferation, immune signatures and TP53 mutations) associated with palbociclib resistance inER+HER2- primary breast cancer (SABCS 2021)
The PALLET phase II randomized neoadjuvant trial of letrozole (LET) ± palbociclib (PALBO) in postmenopausal ER+HER2- primary breast cancer showed that suppression of proliferation as measured by Ki67 was significantly greater with addition of PALBO to LET but did not result in all patients achieving complete cell-cycle arrest, indicating intrinsic resistance in some patients. We observe, confirming previous studies, an association of CDK4/6 inhibitor resistance, high expression of CCNE1 and genes related to interferon gamma signalling. We show that there is an overlap between resistance mechanisms and TP53 mutations. However, ER+HER2- patients with TP53 mutations may still benefit from PALBO adding to suppression of proliferation compared to LET-only treatment.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • IFNG (Interferon, gamma) • IDO1 (Indoleamine 2,3-dioxygenase 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
|
TP53 mutation • ER positive • HER-2 negative • CCNE1 overexpression • RB1 expression • MAP3K1 mutation • CCNE1 expression • CCNE1 elevation
|
Ibrance (palbociclib) • letrozole
over2years
Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome. (PubMed, Cancer Med)
Our cancer genome analysis showed a specific genomic profile of sarcomatoid HCC, which were characterized by a high mutation rate in cell cycle genes particularly CDKN2A. The results indicate CDK4/6 inhibitors including abemaciclib, ribociclib and palbociclib as potential therapeutic targets and may help for therapeutic decision making.
Clinical • Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • FANCM (FA Complementation Group M) • EPHA5 (EPH Receptor A5)
|
CDKN2A mutation • MAP3K1 mutation • FANCM mutation
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
almost3years
MEKK1 Regulates Chemokine Expression in Mammary Fibroblasts: Implications for the Breast Tumor Microenvironment. (PubMed, Front Oncol)
CCL5 and the other MEKK1-dependent chemokines are ligands for the GPCR CCR5, and we show that the CCR5 antagonist Maraviroc strongly inhibits fibroblast-induced tumor cell migration. Finally, we report that fibroblast growth factor 5 (FGF-5) is secreted by MDA-MB 231 cells, that FGF-5 activates MEKK1 effectors ERK1/2 and NFκB in fibroblasts, and that chemical inhibition of NFκB inhibits CCL5 expression. Our results suggest that MEKK1 contributes to the formation of a breast tumor microenvironment that supports metastasis by promoting expression of stroma cell chemokine genes in response to tumor cell-induced paracrine signaling.
Journal
|
MAP2K1 (Mitogen-activated protein kinase kinase 1) • CCL5 (Chemokine (C-C motif) ligand 5) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
|
MAP3K1 mutation